In 2010, the World NET Community Steering Committee proclaimed November 10 as Worldwide Neuroendocrine Cancer...
This past Saturday, a team of Wren employees gathered at the Yale Bowl for the 13th Closer to Free Ride in support...
The Wren Laboratories NETest and its recent expansion into the Chinese Market was the subject of a feature article by Forest Ray in GenomeWeb.com. The article characterized our decision to focus on mRNA as the basis for our diagnostic platform and also discusses a little bit about diagnostics in our pipeline, specifically our PROSTest.
In entering into a distribution agreement with Kindstar Globalgene Technology (Beijing, China), Wren Laboratories has expanded the global availability of our molecular neuroendocrine cancer diagnostic, the NETest. This partnership will double NETest utilization in 2024, providing oncologists for 300,000 NET cancer patients in China the ability to better understand their patient's tumor status and monitor therapy progression.
The NETest leverages both mRNA as its molecular foundation as well as Artificial Intelligence (AI) for gene assessment. introduced in 2014, the test has been utilized over 10,000 by oncologists and their patients to gain a better understanding of their Neuroendocrine Tumor activity and treatment progress.
Yale University, Wren Laboratories and the Barbados Cancer Society have teamed to screen over 500 Barbadian men for molecular signatures indicating the presence of prostate cancer.
The Wren Laboratories NETest was selected as the diagnostic tool in study of a precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients.
Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management
